ImmuneOnco Biopharmaceuticals (Shanghai) Past Earnings Performance
Past criteria checks 0/6
ImmuneOnco Biopharmaceuticals (Shanghai) has been growing earnings at an average annual rate of 5.8%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 37.6% per year.
Key information
5.8%
Earnings growth rate
13.6%
EPS growth rate
Biotechs Industry Growth | 11.0% |
Revenue growth rate | 37.6% |
Return on equity | -50.7% |
Net Margin | -4,845.0% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ImmuneOnco Biopharmaceuticals (Shanghai) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 8 | -379 | 80 | 292 |
30 Sep 23 | 7 | -371 | 84 | 291 |
30 Jun 23 | 5 | -362 | 87 | 289 |
31 Mar 23 | 6 | -382 | 90 | 283 |
31 Dec 22 | 6 | -403 | 93 | 277 |
31 Dec 21 | 14 | -733 | 48 | 176 |
Quality Earnings: 1541 is currently unprofitable.
Growing Profit Margin: 1541 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 1541's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 1541's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1541 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 1541 has a negative Return on Equity (-50.71%), as it is currently unprofitable.